These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 35334224)

  • 21. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.
    Atkin K; Kendall F; Gould D; Freeman H; Liberman J; O'Sullivan D
    Br J Psychiatry; 1996 Oct; 169(4):483-8. PubMed ID: 8894200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
    Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
    JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haematological side effects of clozapine: patient characteristics.
    Miller PR; Cutten AE
    N Z Med J; 1997 Apr; 110(1041):125-7. PubMed ID: 9140414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?
    Schulte PFJ; Veerman SRT; Bakker B; Bogers JPAM; Jongkind A; Cohen D
    Schizophr Res; 2024 Jun; 268():74-81. PubMed ID: 37770377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Burden of Ileus and Pneumonia in Clozapine-Treated Individuals With Schizophrenia: A Finnish 25-Year Follow-Up Register Study.
    Partanen JJ; Häppölä P; Kämpe A; Ahola-Olli A; Hellsten A; Rask SM; Haaki W; Hietala J; Kampman O; Tiihonen J; Tanskanen AJ; ; ; Daly MJ; Ripatti S; Palotie A; Taipale H; Lähteenvuo M; Koskela JT
    Am J Psychiatry; 2024 Oct; 181(10):879-892. PubMed ID: 39262212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Retrospective study of clozapine use in Ile-de-France].
    Hiltgen S; Mantelet S; Pinabel F; Enjaume F
    Encephale; 2006 Oct; 32(5 Pt 1):688-96. PubMed ID: 17099592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study.
    Solmi M; Tiihonen J; Lähteenvuo M; Tanskanen A; Correll CU; Taipale H
    Schizophr Bull; 2022 Jan; 48(1):166-175. PubMed ID: 34286338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
    Passamonti F; Cattaneo C; Arcaini L; Bruna R; Cavo M; Merli F; Angelucci E; Krampera M; Cairoli R; Della Porta MG; Fracchiolla N; Ladetto M; Gambacorti Passerini C; Salvini M; Marchetti M; Lemoli R; Molteni A; Busca A; Cuneo A; Romano A; Giuliani N; Galimberti S; Corso A; Morotti A; Falini B; Billio A; Gherlinzoni F; Visani G; Tisi MC; Tafuri A; Tosi P; Lanza F; Massaia M; Turrini M; Ferrara F; Gurrieri C; Vallisa D; Martelli M; Derenzini E; Guarini A; Conconi A; Cuccaro A; Cudillo L; Russo D; Ciambelli F; Scattolin AM; Luppi M; Selleri C; Ortu La Barbera E; Ferrandina C; Di Renzo N; Olivieri A; Bocchia M; Gentile M; Marchesi F; Musto P; Federici AB; Candoni A; Venditti A; Fava C; Pinto A; Galieni P; Rigacci L; Armiento D; Pane F; Oberti M; Zappasodi P; Visco C; Franchi M; Grossi PA; Bertù L; Corrao G; Pagano L; Corradini P;
    Lancet Haematol; 2020 Oct; 7(10):e737-e745. PubMed ID: 32798473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clozapine treatment in Australia: a review of haematological monitoring.
    Copolov DL; Bell WR; Benson WJ; Keks NA; Strazzeri DC; Johnson GF
    Med J Aust; 1998 May; 168(10):495-7. PubMed ID: 9631674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia.
    Taipale H; Lähteenvuo M; Tanskanen A; Mittendorfer-Rutz E; Tiihonen J
    Schizophr Bull; 2021 Jan; 47(1):23-30. PubMed ID: 33428766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.
    Kuo CJ; Yang SY; Liao YT; Chen WJ; Lee WC; Shau WY; Chang YT; Tsai SY; Chen CC
    Schizophr Bull; 2013 May; 39(3):648-57. PubMed ID: 22282455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the epidemiology of clozapine-associated neutropenia among people on clozapine across Australia and Aotearoa New Zealand: a retrospective cohort study.
    Northwood K; Myles N; Clark SR; Every-Palmer S; Myles H; Kisely S; Warren N; Siskind D
    Lancet Psychiatry; 2024 Jan; 11(1):27-35. PubMed ID: 38040009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
    Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
    Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication and suicide risk in schizophrenia: a nested case-control study.
    Reutfors J; Bahmanyar S; Jönsson EG; Brandt L; Bodén R; Ekbom A; Osby U
    Schizophr Res; 2013 Nov; 150(2-3):416-20. PubMed ID: 24094723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.
    Munro J; O'Sullivan D; Andrews C; Arana A; Mortimer A; Kerwin R
    Br J Psychiatry; 1999 Dec; 175():576-80. PubMed ID: 10789357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ten years of clinical experience with clozapine about 170 patients].
    Levoyer D; Martinet JP; Badiche A; Millet B
    Encephale; 2004; 30(3):285-95. PubMed ID: 15235527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study.
    Tiihonen J; Tanskanen A; Hoti F; Vattulainen P; Taipale H; Mehtälä J; Lähteenvuo M
    Lancet Psychiatry; 2017 Jul; 4(7):547-553. PubMed ID: 28578901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia.
    Schulte PF; Bocxe JT; Doodeman HJ; van Haelst IM; Cohen D
    J Clin Psychopharmacol; 2016 Apr; 36(2):115-9. PubMed ID: 26872114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.